Kareem Rayn, MD

Dr. Kareem Rayn is an Assistant Member in the Department of Radiation Oncology at Moffitt Cancer Center. Dr. Rayn received his MD degree from SUNY Downstate College of Medicine, Brooklyn, New York. He completed a Radiation Oncology Residency at New York Presbyterian/Columbia University Irving Medical Center, New York, where he also served as Chief Resident. Dr. Rayn’s clinical interest is in utilizing the latest techniques in precision-guided radiation therapy, including stereotactic radiation and brachytherapy. His research interests include translational and clinical medicine and leading clinical trials. He is also interested in advancing the ability to tailor individualized radiation therapy plans using genomic and radiomic methods to optimize patient outcomes.

Clinical Trial 24372
Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
Condition: Genitourinary
Intervention: Avelumab (); BMS-936558 (Nivolumab); Cabozantinib (XL 184); E7080 (Lenvatinib); Ipilimumab (); Lenvatinib (Lenvima); MSB00100718C (Avelumab); Nivolumab (Opdivo); Pembrolizumab (Keytruda); Yervoy (Ipilimumab); axitinib (AG-013736)
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Khatri VM, Aboujaoude M, Karapetyan L, Tarhini AA, Brohl AS, Eroglu Z, Markowitz J, Rayn K, Khushalani NI, Wuthrick EJ, Yu HM, Oliver DE, Ahmed KA. Melanoma brain metastases outcomes following nivolumab and relatlimab after ipilimumab and nivolumab progression. J Neurooncol. 2026 Mar.177(1). Pubmedid: 41801545.
• Yacoub I, Rayn K, Choi JI, Bakst R, Chhabra A, Qian JY, Johnstone P, Simone CB. The Role of Radiation, Immunotherapy, and Chemotherapy in the Management of Locally Advanced or Metastatic Cutaneous Malignancies. Cancers (Basel). 2024 Nov.16(23). Pubmedid: 39682109. Pmcid: PMC11640331.
• Rayn K, Magliari A, Clark R, Rosa L, Doucet R, Comeau L, Nichol A, Ruo R, Roberge D. Dosimetric scorecards express precise clinical intent: alternate hippocampal-sparing whole-brain RapidPlan models favoring target coverage and homogeneity at 30 and 20 Gy. Front Oncol. 2024 Nov.14:1465171. Pubmedid: 39664187. Pmcid: PMC11632126.
• Rayn K, Clark R, Hoxha K, Magliari A, Neylon J, Xiang MH, O'Connell DP. An IMRT planning technique for treating whole breast or chest wall with regional lymph nodes on Halcyon and Ethos. J Appl Clin Med Phys. 2024 May.25(5):e14295. Pubmedid: 38335253. Pmcid: PMC11087171.
• Rayn K, Gokhroo G, Jeffers B, Gupta V, Chaudhari S, Clark R, Magliari A, Beriwal S. Multicenter Study of Pelvic Nodal Autosegmentation Algorithm of Siemens Healthineers: Comparison of Male Versus Female Pelvis. Adv Radiat Oncol. 2024 Feb.9(2):101326. Pubmedid: 38405314. Pmcid: PMC10885554.
• Rayn K, Gupta V, Mulinti S, Clark R, Magliari A, Chaudhari S, Garima G, Beriwal S. Evaluation of a deep image-to-image network (DI2IN) auto-segmentation algorithm across a network of cancer centers. J Cancer Res Ther. 2024 Apr.20(3):1020-1025. Pubmedid: 39023610.
• Rayn K, Clark R, Magliari A, Jeffers B, Lavrova E, Lozano IV, Price MJ, Rosa L, Horowitz DP. Scorecards: Quantifying Dosimetric Plan Quality in Pancreatic Ductal Adenocarcinoma Stereotactic Body Radiation Therapy. Adv Radiat Oncol. 2023 Jun.8(6):101295. Pubmedid: 37457822. Pmcid: PMC10344689.
• Bloom JB, Lebastchi AH, Gold SA, Hale GR, Sanford T, Mehralivand S, Ahdoot M, Rayn KN, Czarniecki M, Smith C, Valera V, Wood BJ, Merino MJ, Choyke PL, Parnes HL, Turkbey B, Pinto PA. Use of multiparametric magnetic resonance imaging and fusion-guided biopsies to properly select and follow African-American men on active surveillance. BJU Int. 2019 Nov.124(5):768-774. Pubmedid: 31141307. Pmcid: PMC8288555.
• Mehralivand S, Shih JH, Harmon S, Smith C, Bloom J, Czarniecki M, Gold S, Hale G, Rayn K, Merino MJ, Wood BJ, Pinto PA, Choyke PL, Turkbey B. A Grading System for the Assessment of Risk of Extraprostatic Extension of Prostate Cancer at Multiparametric MRI. Radiology. 2019 Mar.290(3):709-719. Pubmedid: 30667329. Pmcid: PMC6394788.
• Gold SA, VanderWeele DJ, Harmon S, Bloom JB, Karzai F, Hale GR, Marhamati S, Rayn KN, Mehralivand S, Merino MJ, Gulley JL, Bilusic M, Madan RA, Choyke PL, Turkbey B, Dahut W, Pinto PA. mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy. Urol Oncol. 2019 Jun.37(6):352.e25-352.e30. Pubmedid: 31000430. Pmcid: PMC8132295.
• Baiocco JA, Ball MW, Pappajohn AK, Rayn KN, Bratslavsky G, Boyle SL, Linehan WM, Metwalli AR. A comparison of outcomes for standard and multiplex partial nephrectomy in a solitary kidney: The National Cancer Institute experience. Urol Oncol. 2019 Jun.37(6):356.e1-356.e7. Pubmedid: 30902489. Pmcid: PMC6535179.
• Bloom JB, Hale GR, Gold SA, Rayn KN, Smith C, Mehralivand S, Czarniecki M, Valera V, Wood BJ, Merino MJ, Choyke PL, Parnes HL, Turkbey B, Pinto PA. Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: Role of a Negative Confirmatory Magnetic Resonance Imaging-Ultrasound Fusion Biopsy. J Urol. 2019 Jan.201(1):84-90. Pubmedid: 30577395. Pmcid: PMC8274955.
• Gold SA, Hale GR, Bloom JB, Smith CP, Rayn KN, Valera V, Wood BJ, Choyke PL, Turkbey B, Pinto PA. Follow-up of negative MRI-targeted prostate biopsies: when are we missing cancer?. World J Urol. 2019 Feb.37(2):235-241. Pubmedid: 29785491.
• Rayn KN, Hale GR, Bloom JB, Gold SA, Carvalho FLF, Mehralivand S, Czarniecki M, Wood BJ, Merino MJ, Choyke P, Türkbey B, Pinto PA, Agarwal PK. Incidental bladder cancers found on multiparametric MRI of the prostate gland: a single center experience. Diagn Interv Radiol. 2018 Sep.24(5):316-320. Pubmedid: 30211685. Pmcid: PMC6135055.
• Rayn KN, Elnabawi YA, Sheth N. Clinical implications of PET/CT in prostate cancer management. Transl Androl Urol. 2018 Oct.7(5):844-854. Pubmedid: 30456187. Pmcid: PMC6212623.
• Rayn KN, Bloom JB, Gold SA, Hale GR, Baiocco JA, Mehralivand S, Czarniecki M, Sabarwal VK, Valera V, Wood BJ, Merino MJ, Choyke P, Turkbey B, Pinto PA. Added Value of Multiparametric Magnetic Resonance Imaging to Clinical Nomograms for Predicting Adverse Pathology in Prostate Cancer. J Urol. 2018 Nov.200(5):1041-1047. Pubmedid: 29852182. Pmcid: PMC7983159.
• Hale GR, Czarniecki M, Cheng A, Bloom JB, Seifabadi R, Gold SA, Rayn KN, Sabarwal VK, Mehralivand S, Choyke PL, Turkbey B, Wood B, Pinto PA. Comparison of Elastic and Rigid Registration during Magnetic Resonance Imaging/Ultrasound Fusion-Guided Prostate Biopsy: A Multi-Operator Phantom Study. J Urol. 2018 Nov.200(5):1114-1121. Pubmedid: 29940248. Pmcid: PMC7984721.
• Rayn KN, Hale GR, Grave GP, Agarwal PK. New therapies in nonmuscle invasive bladder cancer treatment. Indian J Urol. 2018 Jan.34(1):11-19. Pubmedid: 29343907. Pmcid: PMC5769243.
• Sabarwal VK, Ritchie C, Rayn K, Turkbey B, Pinto P. The disappearing PI-RADS 5 prostate lesion. Can J Urol. 2018 Apr.25(2):9281-9283. Pubmedid: 29680007.
• Bloom JB, Gold SA, Hale GR, Rayn KN, Sabarwal VK, Bakhutashvili I, Valera V, Turkbey B, Pinto PA, Wood BJ. "Super-active surveillance": MRI ultrasound fusion biopsy and ablation for less invasive management of prostate cancer. Gland Surg. 2018 Apr.7(2):166-187. Pubmedid: 29770311. Pmcid: PMC5938261.